Adagene’s ADG126 Shows Promise in MSS CRC Therapy
Company Announcements

Adagene’s ADG126 Shows Promise in MSS CRC Therapy

Adagene (ADAG) has released an update.

Adagene’s new clinical data, presented at the ESMO Congress, shows promising results for ADG126, a novel anti-CTLA-4 antibody, when used in combination with pembrolizumab for the treatment of metastatic microsatellite-stable colorectal cancer (MSS CRC). The treatment demonstrated an overall response rate of 24%, a median progression-free survival of 8.5 months, and an encouraging safety profile with low rates of severe treatment-related adverse events. This combination therapy offers a potential new treatment option for MSS CRC patients, including those with liver metastases.

For further insights into ADAG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAdagene Unveils Promising Data for Cancer Therapy
TheFlyAdagene presents data on ADG126 at SITC Annual Meeting
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App